Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can talking it out ease PTSD in cancer patients during a pandemic?

NCT ID NCT04747249

Symptom relief Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see if this supportive therapy could lower stress, improve resilience, and enhance sleep and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
psychological support (monthly interviews)
What this could lead to
If it works, this could point toward a simple, supportive therapy to reduce PTSD and improve quality of life for cancer patients during health crises.
What could go wrong
This is a very small, completed study with only 29 participants and no control group, so results may not apply broadly. The intervention is brief and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Jun 2021

Finished

Sep 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient ≥ 18 years old * Patient treated or followed up for a solid tumour at the François Baclesse Centre * Patient with a score suggesting moderate or high posttraumatic stress symptoms (IES-R score ≥ 24) related to the COVID-19 epidemic * The patient's state of health is compatible with the programme: psychological care for 6 months. * Information note signed by the patient * Any associated geographical, social or psychopathological conditions that might compromise the patient's ability to participate in the study Exclusion Criteria: * Patient with no symptoms suggestive of moderate or high post-traumatic stress (IES-R score \<24) * Patient deprived of liberty or under guardianship * Patient already receiving psychological care * Patient whose diagnosis of the disease was made within one month prior to the proposal for participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma COVID-19 neoplasm post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 Post-traumatic stress disorder Solid carcinoma

Contacts and locations

Locations

  • Centre Francois Baclesse

    Caen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.